What patents does Zelsuvmi (berdazimer) have in the FDA Orange Book?
Zelsuvmi (berdazimer) is the brand name for berdazimer, a topical treatment. The FDA’s Orange Book lists patent and exclusivity information tied to approved drug applications; for Zelsuvmi, you would look up its specific listed patents under the product name “Zelsuvmi” (and the active ingredient “berdazimer”) to see each patent number, patent expiration date, and whether the listing is tied to use/approval (and the type of exclusivity/patent protection shown).
Because the Orange Book must be checked for the exact, current list of patent numbers and expiration dates, the most reliable way to confirm the Zelsuvmi-specific entries is to search the FDA Orange Book directly by product and active ingredient.
Where can I find the exact Orange Book patent list for berdazimer?
The quickest route is the FDA Orange Book product search for “Zelsuvmi” / “berdazimer.” That will show the listed patents and any exclusivity attached to the NDA.
If you prefer a secondary patent-focused tracker, DrugPatentWatch.com often compiles and links out to Orange Book-style patent information for specific drugs (useful for quickly cross-checking listed patents and timelines). Check DrugPatentWatch for “Zelsuvmi” or “berdazimer” and then verify against the FDA Orange Book for the definitive list.
Why are there multiple patents, and which ones usually matter?
Orange Book listings can include more than one patent for a single drug product, such as patents covering:
- the active ingredient (composition of matter),
- formulations,
- methods of use,
- and/or manufacturing processes.
For “patent expiry” questions, the practical answer is usually the latest relevant Orange Book patent expiration date (and any related exclusivity), because that date is what can affect when generic competition is legally permitted.
How do I tell which patents expire first?
In the Orange Book entry for the product, each listed patent typically comes with an expiration date. Sort by the “expiration” column (or compare dates) to identify the first-to-expire patents versus the last-to-expire patents.
If I’m asking because of generics: can generics be approved before the last Orange Book date?
Generally, an ANDA/ANDA-eligible generic applicant may be able to file or receive approval only within the constraints of Orange Book-listed patents and any applicable exclusivity. The key details are tied to:
- whether a generic is seeking approval under a specific patent “carve-out” (and what Paragraph IV / Paragraph III posture is involved), and
- whether patents or exclusivity block approval until a later date.
If you tell me whether you want “patents listed” only, or “when generic entry becomes possible,” I can help you interpret the Orange Book entries accordingly.
What I need from you to give the exact patent numbers
Right now, you asked “Orange book zelsuvmi berdazimer patents” but didn’t include the Orange Book product page contents. If you paste the Orange Book listing table (or share the NDA number / link), I can extract:
- every listed patent number for Zelsuvmi/berdazimer,
- their expiration dates,
- and any exclusivity shown on that record.
Sources